Moximed is a pioneering medical device company addressing a significant gap in the treatment of knee osteoarthritis with its MISHA Knee System, an implantable shock absorber (ISA). The device is commercially available following successful clinical studies demonstrating high rates of pain relief and functional improvement. Led by an experienced team with a history of scaling and exiting medtech companies, Moximed is positioned to capture a share of the large and growing market for early-intervention osteoarthritis treatments.
OrthopedicsOsteoarthritis
Technology Platform
Implantable Shock Absorber (ISA) platform; a metal-and-polymer device designed to be implanted parallel to the knee joint to absorb load and unload the diseased compartment.
Funding History
4
Total raised:$132M
Series D$30MNew Enterprise Associates (NEA)
Series C$40MNew Enterprise Associates (NEA)
Series B$42MNew Enterprise Associates (NEA)
Series A$20MNew Enterprise Associates (NEA)
Opportunities
Moximed addresses a massive unmet need in the 'treatment gap' for patients with early-to-mid-stage knee OA who fail conservative care but are not candidates for knee replacement.
The shift towards value-based care and earlier joint preservation interventions creates a favorable market environment.
The underlying ISA platform technology offers potential for expansion into other joints like the ankle or hip.
Risk Factors
Key risks include commercial execution challenges in changing physician behavior and securing insurance reimbursement, potential future competition, and the need to generate long-term durability and outcomes data post-market.
The novel nature of the device requires significant surgeon education and training.
Competitive Landscape
The MISHA Knee System is first-in-class as an implantable load absorber. It competes indirectly with non-surgical options (braces, injections), high tibial osteotomy, and unicompartmental/total knee arthroplasty. It faces potential future competition from other load-sharing devices or advanced biologic therapies under development.
